Clinical evidence for immune-based strategies in early-line multiple myeloma: current challenges in decision-making for subsequent therapy

HIGHLIGHTS

• who: Noopur Raje from the (UNIVERSITY) have published the research work: Clinical evidence for immune-based strategies in early-line multiple myeloma: current challenges in decision-making for subsequent therapy, in the Journal: (JOURNAL) of 23/02/2023
• what: Currently, pomalidomide-, carfilzomib- and antiCD38-based regimens are options considered for next-line therapy after either lenalidomide or daratumumab and will be the focus of this review.
• future: Blood Cancer Journal 1341 Future directions for therapy in RRMM Additional therapies and investigations currently underway or recently approved as new therapeutic options for patients with . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.